Summary relative risk (SRR) of site-specific cancers following NMSC, BCC, and SCC among registry-based studies
| Site of second primary cancer | NMSC SRR (95% CI)* | NMSC: males SRR (95% CI)* | NMSC: females SRR (95% CI)* | BCC SRR (95% CI)* | SCC SRR (95% CI)* |
|---|---|---|---|---|---|
| Lung | 1.23 (1.13-1.33) | 1.27 (1.16-1.39) | 1.19 (1.06-1.33) | 1.13 (1.01-1.27) | 1.34 (1.22-1.47) |
| Breast | 1.04 (0.96-1.14) | —† | 1.04 (0.96-1.14) | 1.08 (0.99-1.19) | 0.97 (0.88-1.08) |
| Colorectal | 1.05 (0.97-1.13) | 1.05 (0.95-1.16) | 1.03 (0.94-1.13) | 1.02 (0.93-1.13) | 1.03 (0.93-1.15) |
| Melanoma | 2.74 (2.49-3.02) | 2.73 (2.52-2.96) | 2.61 (2.24-3.05) | 2.75 (2.39-3.16) | 2.84 (2.45-3.29) |
| Pancreas | 0.94 (0.82-1.07) | 1.07 (0.97-1.18) | 0.91 (0.78-1.06) | —‡ | —‡ |
| Leukemia | 1.26 (1.04-1.52) | 1.45 (1.17-1.79) | 1.24 (0.99-1.55) | 1.12 (0.93-1.35) | 1.45 (0.93-2.11) |
| Cervix | 0.93 (0.62-1.41) | —† | 0.93 (0.62-1.41) | 0.84 (0.50-1.41) | —‡ |
| Non–Hodgkin lymphoma | 1.58 (1.37-1.81) | 1.56 (1.33-1.84) | 1.58 (1.37-1.82) | 1.39 (1.22-1.58) | 2.00 (1.80-2.22) |
| Myeloma | 1.18 (1.06-1.32) | —‡ | —‡ | —‡ | —‡ |
| Salivary gland | 4.57 (2.92-7.15) | 5.22 (3.32-8.22) | 3.65 (1.91-6.95) | —‡ | 7.15 (4.09-12.52) |
| Thyroid | 1.28 (0.95-1.71) | 1.72 (0.55-5.33) | 1.23 (0.99-1.53) | 1.24 (0.92-1.67) | —‡ |
| Prostate | 1.04 (0.98-1.12) | 1.04 (0.98-1.12) | —† | 1.07 (0.97-1.17) | 1.00 (0.94-1.07) |
| Lip | 2.38 (2.03-2.79) | 2.09 (1.88-2.31) | 4.45 (2.76-7.19) | —‡ | 3.79 (3.15-4.57) |
| Mouth and pharynx | 1.69 (1.31-2.18) | 1.94 (1.50-2.49) | 1.87 (1.26-2.78) | 1.32 (1.13-1.55) | 2.05 (1.33-3.19) |
| Esophagus | 1.06 (0.85-1.32) | 1.15 (0.92-1.45) | 1.11 (0.90-1.36) | 0.90 (0.67-1.21) | 1.21 (0.83-1.74) |